PT141
Metabolite of Melanotan II developed specifically for sexual dysfunction. FDA approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; this approval does not extend to Melanotan II.
Regulatory status (as of Sept 2026)
Approved prescription product (Vyleesi) for premenopausal women with acquired, generalized HSDD. Use in men or postmenopausal women is off-label. Not a 503A compounding-list item addressed by the April 2026 removals or the July 2026 PCAC votes.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote1 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
PT-141 (Bremelanotide) is an FDA-approved prescription drug. Metabolite of Melanotan II developed specifically for sexual dysfunction.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | FDA-approved |
| Dosing | Published research: 1.75 mg subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder (RECONNECT… details1.75 mg subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder (RECONNECT phase 3 programme, two trials plus a 52-week open-label extension with 684 participants)Community-reportedCommunity-reported: 1.75 mg as needed, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It switches on melanocortin receptors; how this improves low sexual desire in women is not known. Per the FDA label (Vyleesi): a melanocortin receptor agonist that nonselectively activates several receptor subtypes (potency order MC1R, MC4R, MC3R, MC5R, MC2R); at therapeutic doses, binding to MC1R and MC4R is most relevant. The mechanism by which it improves hypoactive sexual desire disorder in women is unknown. MC1R binding on melanocytes leads to increased pigmentation.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported 1.75 mg as needed (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| PT-141 (Bremelanotide) | No published PK data found | Subcutaneous injection | FDA-approved |
| Gonadorelin | No published PK data found | Subcutaneous injection | Discontinued |
| Kisspeptin-10 | Kisspeptin-10: ~4 min (mice, IV/systemic); ~28 min (27.6 ± 1.1) is kisspeptin-54 in human males (IV infusion) | Subcutaneous or IV injection | Phase 1 / early human |
| Triptorelin | Geometric mean terminal half-life 2.8 h in healthy males after a 0.5 mg IV bolus; 6.6-7.7 h in males with renal or hepatic impairment (three-compartment model) | Intramuscular injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Sexual Health category. View All Sexual Health Peptides
Sexual Health
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.